查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1404800

流感疫苗市场规模、份额和趋势分析报告：2024-2030年按疫苗类型、适应症、年龄层、给药途径、配销通路、地区和细分市场预测

Influenza Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Inactivated, Live Attenuated), By Indication, By Age Group, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

流感疫苗市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球流感疫苗市场规模将达到125.8亿美元，2024年至2030年复合年增长率为6.98%。

免疫计划的增加、对流感和流感的认识不断提高以及流感疫苗研发活动的激增预计将推动市场成长。将流感疫苗纳入各国免疫计画以及世界各地越来越多的免疫意识提升计画也有望促进市场成长。

全球正在进行的国家流感疫苗接种计划预计将推动市场发展。例如，通用流感疫苗接种计划和 NIP 疫苗接种计划等计划是一些主要的免疫计划。这些计划向所有符合条件的个人提供免费流感疫苗。这些计划的主要目标是消除流感样疾病的风险。

三价和四价疫苗是市售的流感疫苗。其中，四价疫苗是最优选的类型，因为其高效且能够预防两种乙型流感病毒和两种甲型流感病毒。各大公司都在从事四价疫苗产品开发的研究工作。例如，2022 年 11 月，辉瑞 (Pfizer Inc.) 和 BioNTech SE 宣布，他们将推进针对 COVID-19 和流感的基于 mRNA 的联合候选疫苗的开发，以缓解两种危及生命的呼吸道疾病。

此外，随着新病毒株的出现，科学家正在设计疫苗接种策略，以预防多种流感病毒株，并为个人提供持久的免疫力。例如，2022年3月，墨尔本莫纳什大学和新加坡国立大学的科学家在《美国科学院院刊》上发表了他们的研究结果。这项研究引入了一个平台，可以有效地将候选疫苗 M2e 递送至免疫细胞，并实现针对不同病毒株的长期免疫。

此外，主要市场参与企业的各种措施可能为市场提供指数级成长机会。例如，2020年2月，雅培公司宣布在印度推出针对四种病毒株的灭活四价疫苗。此外，2021 年 1 月，ModernaTX, Inc. 宣布计划使用 mRNA 技术製造和开发 Nipah、HIV 和流感病毒疫苗。

流感疫苗市场报告亮点

  • 2023年，灭活疫苗占最大市场占有率，达到91.94%，预计在预测期内成长最快。
  • 2023年四价疫苗占86.77%的份额，预计在预测期内将成长最快。这种增长是由于它们对病毒感染的高效性、成本效益以及在诊所和医院的容易获得。
  • 由于联合国儿童基金会、全球疫苗免疫联盟和泛美卫生组织积极努力增加免疫接种和疫苗的大量采购，2023年成人细分市场的销售份额最大，为78.64%。
  • 注射剂产业2023年销售量占比最大，为92.09%。该细分市场的高成长归因于市场上有大量候选肌内疫苗。
  • 2023年医院和药局将拥有最大的销售份额，达到54.00%。医院的大量疫苗供应预计将为该领域提供利润丰厚的商机。
  • 由于有效产品的快速推出以及该地区技术先进的疫苗生产设施，北美以 53.35% 的份额领先市场。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章流感疫苗市场-产业展望

  • 市场体系展望
  • 2022 年疫苗类型普及与成长前景图
  • 市场动态
  • SWOT 分析，按因素（政治/法律、经济、技术）
  • 产业分析-波特五力分析
  • 管道分析
  • 价格分析
  • 按国家/地区分類的疫苗接种覆盖率

第四章 疫苗类业务分析

  • 流感疫苗市场：疫苗种类波动分析
  • 按类型
    • 已被禁用
    • 活腐烂

第五章 指标业务分析

  • 流感疫苗市场：适应症变异分析
  • 按指示
    • 四价
    • 三价

第六章依年龄组别进行的业务分析

  • 流感疫苗市场：年龄层变化分析
  • 按年龄组别
    • 儿童
    • 成人

第七章给药途径业务分析

  • 流感疫苗市场：给药途径变异分析
  • 依给药途径
    • 注射
    • 滴鼻剂

第八章配销通路业务分析

  • 流感疫苗市场：配销通路波动分析
  • 按配销通路
    • 医院和药房
    • 政府和机构用品
    • 其他的

第九章流感疫苗市场：按疫苗类型、适应症、年龄层、给药途径和配销通路分類的区域估计和趋势分析

  • 流感疫苗市场：区域展望
  • 北美洲
    • 2018年至2030年北美流感疫苗市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 2018年至2030年欧洲流感疫苗市场估计与预测
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030年亚太地区流感疫苗市场估计与预测
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲流感疫苗市场估计与预测
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 2018-2030 年 MEA 流感疫苗市场估计与预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第10章竞争形势

  • 公司分类
  • 参与企业概况
  • 财务绩效
  • 产品基准评效
  • 公司市场定位
  • 公司简介
    • GSK plc
    • AstraZeneca
    • SINOVAC
    • Vaxess Technologies Inc
    • Pfizer Inc
    • CSL Limited
    • EMERGENT
    • Merck &Co., Inc.
    • Viatris Inc.
    • OSIVAX, EMERGEX VACCINES
  • 2022 年公司市场占有率分析
  • 企业热力图分析
  • 策略规划
    • 扩张
    • 合作
    • 合伙
    • 新产品发布
    • 其他的

第11章结论

Product Code: GVR-4-68040-019-6

Influenza Vaccine Market Growth & Trends:

The global influenza vaccine market size is expected to reach USD 12.58 billion by 2030 and is set to expand at 6.98% CAGR from 2024 to 2030, according to a new report by Grand View Research, Inc. The increase in immunization programs, rising awareness regarding flu and influenza, and surge in R&D activities pertaining to flu vaccines are anticipated to propel market growth. In addition, the inclusion of the influenza vaccine in various national immunization programs and increasing awareness programs for immunizations across the globe is anticipated to boost the market growth.

The ongoing influenza vaccination national schemes globally are anticipated to propel the market. For instance, programs such as Universal Influenza Immunization Program and NIP Vaccination Programs among others are some of the key immunization programs. These offer flu vaccines free of cost to all the target population. The key objective of such programs is to eliminate the risk of flu-like disorders.

Trivalent and Quadrivalent vaccines are commercially available influenza vaccines. Among these, the quadrivalent vaccines are the most preferred type owing to their high efficacy and their ability to combat two influenza-B viruses and two influenza-A viruses. Leading companies are undertaking efforts to conduct research studies for quadrivalent product development. For instance, in November 2022, Pfizer Inc. and BioNTech SE announced the advancement of an mRNA-based combination vaccine candidate for COVID-19 and influenza to mitigate two life-threatening respiratory conditions.

Moreover, due to the emergence of new strains, scientists are devising a vaccination strategy that could prevent the flu virus with multiple strains and achieve long-lasting immunity in an individual. For instance, in March 2022, scientists from Monash University, Melbourne, and the National University of Singapore published research in the 'Proceedings of the National Academy of Sciences'. This research featured a platform to efficiently offer vaccine candidate M2e to the immune cells to attain long-lasting immunity against different virus strains.

Furthermore, various initiatives undertaken by leading market participants are likely to provide exponential growth opportunities for the market. For instance, in February 2020, Abbott announced the launch of inactivated quadrivalent vaccine for protection against four virus strains in India. In addition, in January 2021, ModernaTX, Inc. announced the company's plans to use mRNA technology to manufacture and develop Nipah, HIV, and flu virus vaccines.

Influenza Vaccine Market Report Highlights:

  • Inactivated vaccines held the largest market share of 91.94% in 2023 and are anticipated to grow at the fastest rate during the forecast period.
  • The quadrivalent segment dominated the market with a share of 86.77% in 2023 and is expected to grow at the fastest growth rate over the forecast period. The growth is due to high efficacy against viral infections, cost-effectiveness, and easy availability in clinics & hospitals.
  • The adult segment held the largest revenue share of 78.64% in 2023 owing to favorable efforts to increase immunization and high vaccine dose procurement by UNICEF, GAVI, and PAHO.
  • The injection segment held the largest revenue share of 92.09% in 2023. High growth of the segment accounted for a large number of intramuscular vaccine candidates available in market.
  • Hospitals & pharmacies captured the largest revenue share of 54.00% in 2023. Large quantity of vaccine supply from hospitals is anticipated to generate lucrative revenue opportunities for the segment.
  • North America led the market with a 53.35% share due to rapid launch of effective products along with technologically advanced vaccine production facilities across the region.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 List Of Secondary Sources
  • 1.8 Objectives
    • 1.8.1 Objective 1
    • 1.8.2 Objective 2
    • 1.8.3 Objective 3
    • 1.8.4 Objective 4
  • 1.9 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Vaccine Type And Indication Snapshot
  • 2.3 Age Group And Route Of Administration Snapshot
  • 2.4 Distribution Channel Snapshot
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Influenza Vaccines Market - Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Biologics Market
    • 3.1.2 Vaccine Market
    • 3.1.3 Related/Ancillary Market Outlook (Meningococcal Vaccines Market)
  • 3.2 Penetration & Growth Prospect Mapping For Vaccine Type, 2022
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers
      • 3.3.1.1 Increase In Prevalence Of Influenza
      • 3.3.1.2 Active Government Support To Promote Vaccination
      • 3.3.1.3 Strategic Initiatives Undertaken By Leading Players
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 High Cost Associated With Storage And Supply of Vaccines
      • 3.3.2.2 Longer Timeline for Vaccine Production
  • 3.4 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • 3.5 Industry Analysis - Porter's
  • 3.6 Pipeline Analysis
  • 3.7 Pricing Analysis
  • 3.8 Vaccination Rate, by Country

Chapter 4 Vaccine Type Business Analysis

  • 4.1 Influenza Vaccine Market: Vaccine Type Movement Analysis
  • 4.2 Influenza Vaccine Market Estimates & Forecast, By Type (USD Million)
    • 4.2.1 Inactivated
    • 4.2.2 Live Attenuated

Chapter 5 Indication Business Analysis

  • 5.1 Influenza Vaccine Market: Indication Movement Analysis
  • 5.2 Influenza Vaccine Market Estimates & Forecast, By Indication (USD Million)
    • 5.2.1 Quadrivalent
    • 5.2.2 Trivalent

Chapter 6 Age Group Business Analysis

  • 6.1 Influenza Vaccine Market: Age Group Movement Analysis
  • 6.2 Influenza Vaccine Market Estimates & Forecast, By Age Group (USD Million)
    • 6.2.1 Pediatric
    • 6.2.2 Adults

Chapter 7 Route Of Administration Business Analysis

  • 7.1 Influenza Vaccine Market: Route of Administration Movement Analysis
  • 7.2 Influenza Vaccine Market Estimates & Forecast, By Route of Administration (USD Million)
    • 7.2.1 Injection
    • 7.2.2 Nasal Spray

Chapter 8 Distribution Channel Business Analysis

  • 8.1 Influenza Vaccine Market: Distribution Channel Movement Analysis
  • 8.2 Influenza Vaccine Market Estimates & Forecast, By Distribution Channel (USD Million)
    • 8.2.1 Hospitals & Pharmacies
    • 8.2.2 Government And Institutional Supply
    • 8.2.3 Others

Chapter 9 Influenza Vaccine Market: Regional Estimates and Trend Analysis, By Vaccine Type, Indication, Age Group, Route of Administration, and Distribution Channel

  • 9.1 Influenza Vaccine Market: Regional Outlook
  • 9.2 North America
    • 9.2.1 North America Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 U.S. Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.2.2.3 Competitive Scenario
      • 9.2.2.4 Regulatory Framework
      • 9.2.2.5 Reimbursement Scenario
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Canada Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.2.3.3 Competitive Scenario
      • 9.2.3.4 Regulatory Framework
      • 9.2.3.5 Reimbursement Scenario
  • 9.3 Europe
    • 9.3.1 Europe Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 UK
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 UK Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.2.3 Competitive Scenario
      • 9.3.2.4 Regulatory Framework
      • 9.3.2.5 Reimbursement Scenario
    • 9.3.3 Germany
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Germany Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.3.3 Competitive Scenario
      • 9.3.3.4 Regulatory Framework
      • 9.3.3.5 Reimbursement Scenario
    • 9.3.4 France
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 France Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.4.3 Competitive Scenario
      • 9.3.4.4 Regulatory Framework
      • 9.3.4.5 Reimbursement Scenario
    • 9.3.5 Spain
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Spain Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.5.3 Competitive Scenario
      • 9.3.5.4 Regulatory Framework
      • 9.3.5.5 Reimbursement Scenario
    • 9.3.6 Italy
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Italy Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.6.3 Competitive Scenario
      • 9.3.6.4 Regulatory Framework
      • 9.3.6.5 Reimbursement Scenario
    • 9.3.7 Denmark
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Denmark Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.7.3 Competitive Scenario
      • 9.3.7.4 Regulatory Framework
      • 9.3.7.5 Reimbursement Scenario
    • 9.3.8 Sweden
      • 9.3.8.1 Key Country Dynamics
      • 9.3.8.2 Sweden Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.8.3 Competitive Scenario
      • 9.3.8.4 Regulatory Framework
      • 9.3.8.5 Reimbursement Scenario
    • 9.3.9 Norway
      • 9.3.9.1 Key Country Dynamics
      • 9.3.9.2 Norway Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.9.3 Competitive Scenario
      • 9.3.9.4 Regulatory Framework
      • 9.3.9.5 Reimbursement Scenario
      • 9.3.9.6 Rest Of Europe Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Japan Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.2.3 Competitive Scenario
      • 9.4.2.4 Regulatory Framework
      • 9.4.2.5 Reimbursement Scenario
    • 9.4.3 China
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 China Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.3.3 Competitive Scenario
      • 9.4.3.4 Regulatory Framework
      • 9.4.3.5 Reimbursement Scenario
    • 9.4.4 India
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 India Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.4.3 Competitive Scenario
      • 9.4.4.4 Regulatory Framework
      • 9.4.4.5 Reimbursement Scenario
    • 9.4.5 Australia
      • 9.4.5.1 Key Country Dynamics
      • 9.4.5.2 Australia Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.5.3 Competitive Scenario
      • 9.4.5.4 Regulatory Framework
      • 9.4.5.5 Reimbursement Scenario
    • 9.4.6 Thailand
      • 9.4.6.1 Key Country Dynamics
      • 9.4.6.2 Thailand Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.6.3 Competitive Scenario
      • 9.4.6.4 Regulatory Framework
      • 9.4.6.5 Reimbursement Scenario
    • 9.4.7 South Korea
      • 9.4.7.1 Key Country Dynamics
      • 9.4.7.2 South Korea Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.7.3 Competitive Scenario
      • 9.4.7.4 Regulatory Framework
      • 9.4.7.5 Reimbursement Scenario
      • 9.4.7.6 Rest Of Asia Pacific Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Brazil Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.2.3 Competitive Scenario
      • 9.5.2.4 Regulatory Framework
      • 9.5.2.5 Reimbursement Scenario
    • 9.5.3 Mexico
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Mexico Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.3.3 Competitive Scenario
      • 9.5.3.4 Regulatory Framework
      • 9.5.3.5 Reimbursement Scenario
    • 9.5.4 Argentina
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Argentina Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.4.3 Competitive Scenario
      • 9.5.4.4 Regulatory Framework
      • 9.5.4.5 Reimbursement Scenario
      • 9.5.4.6 Rest Of Latin America Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.6 MEA
    • 9.6.1 MEA Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 Key Country Dynamics
      • 9.6.2.2 South Africa Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.2.3 Competitive Scenario
      • 9.6.2.4 Regulatory Framework
      • 9.6.2.5 Reimbursement Scenario
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Key Country Dynamics
      • 9.6.3.2 Saudi Arabia Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.3.3 Competitive Scenario
      • 9.6.3.4 Regulatory Framework
      • 9.6.3.5 Reimbursement Scenario
    • 9.6.4 UAE
      • 9.6.4.1 Key Country Dynamics
      • 9.6.4.2 UAE Influenza Vaccine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.4.3 Competitive Scenario
      • 9.6.4.4 Regulatory Framework
      • 9.6.4.5 Reimbursement Scenario
    • 9.6.5 Kuwait
      • 9.6.5.1 Key Country Dynamics
      • 9.6.5.2 Kuwait Influenza Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 9.6.5.3 Competitive Scenario
      • 9.6.5.4 Regulatory Framework
      • 9.6.5.5 Reimbursement Scenario
      • 9.6.5.6 Rest of MEA Influenza Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Competitive Landscape

  • 10.1 Company Categorization
  • 10.2 Participant's Overview
  • 10.3 Financial Performance
  • 10.4 Product Benchmarking
  • 10.5 Company Market Positioning
  • 10.6 Company Profiles
    • 10.6.1 GSK plc
      • 10.6.1.1 Company overview
      • 10.6.1.2 Financial performance
      • 10.6.1.3 Product benchmarking
      • 10.6.1.4 Strategic Initiatives
    • 10.6.2 AstraZeneca
      • 10.6.2.1 Company overview
      • 10.6.2.2 Financial performance
      • 10.6.2.3 Product benchmarking
      • 10.6.2.4 Strategic Initiatives
    • 10.6.3 SINOVAC
      • 10.6.3.1 Company overview
      • 10.6.3.2 Financial performance
      • 10.6.3.3 Product benchmarking
      • 10.6.3.4 Strategic Initiatives
    • 10.6.4 Vaxess Technologies Inc
      • 10.6.4.1 Company overview
      • 10.6.4.2 Financial performance
      • 10.6.4.3 Product benchmarking
      • 10.6.4.4 Strategic Initiatives
    • 10.6.5 Pfizer Inc
      • 10.6.5.1 Company overview
      • 10.6.5.2 Financial performance
      • 10.6.5.3 Product benchmarking
      • 10.6.5.4 Strategic Initiatives
    • 10.6.6 CSL Limited
      • 10.6.6.1 Company overview
      • 10.6.6.2 Financial performance
      • 10.6.6.3 Product benchmarking
      • 10.6.6.4 Strategic Initiatives
    • 10.6.7 EMERGENT
      • 10.6.7.1 Company overview
      • 10.6.7.2 Financial performance
      • 10.6.7.3 Product benchmarking
      • 10.6.7.4 Strategic initiatives
    • 10.6.8 Merck & Co., Inc.
      • 10.6.8.1 Company overview
      • 10.6.8.2 Financial performance
      • 10.6.8.3 Product benchmarking
      • 10.6.8.4 Strategic initiatives
    • 10.6.9 Viatris Inc.
      • 10.6.9.1 Company overview
      • 10.6.9.2 Financial performance
      • 10.6.9.3 Product benchmarking
      • 10.6.9.4 Strategic initiatives
    • 10.6.10 OSIVAX, EMERGEX VACCINES
      • 10.6.10.1 Company overview
      • 10.6.10.2 Financial performance
      • 10.6.10.3 Product benchmarking
      • 10.6.10.4 Strategic initiatives
  • 10.7 Company Market Share Analysis, 2022
  • 10.8 Company Heat Map Analysis
  • 10.9 Strategy Mapping
    • 10.9.1 Expansion
    • 10.9.2 Collaborations
    • 10.9.3 Partnership
    • 10.9.4 New Product Launches
    • 10.9.5 Others

Chapter 11 Conclusion

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global Influenza Vaccine Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 6 Global Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 7 Global Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 Global Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 9 Global Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 North America Influenza Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 11 North America Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 12 North America Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 13 North America Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 North America Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 15 North America Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 U.S. Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 17 U.S. Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 18 U.S. Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 U.S. Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 20 U.S. Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Canada Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 22 Canada Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 23 Canada Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 Canada Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 25 Canada Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Europe Influenza Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 27 Europe Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 28 Europe Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 29 Europe Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Europe Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 31 Europe Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Germany Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 33 Germany Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 34 Germany Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Germany Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 36 Germany Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 UK Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 38 UK Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 39 UK Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 UK Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 41 UK Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 France Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 43 France Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 44 France Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 France Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 46 France Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Italy Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 48 Italy Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 49 Italy Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Italy Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 51 Italy Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Spain Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 53 Spain Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 54 Spain Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 Spain Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 56 Spain Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 Denmark Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 58 Denmark Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 59 Denmark Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 Denmark Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 61 Denmark Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Norway Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 63 Norway Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 64 Norway Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Norway Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 66 Norway Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Sweden Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 68 Sweden Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 69 Sweden Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Sweden Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 71 Sweden Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific Influenza Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 77 Asia Pacific Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Japan Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 79 Japan Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 80 Japan Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 81 Japan Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 82 Japan Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 China Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 84 China Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 85 China Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 China Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 87 China Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 India Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 89 India Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 90 India Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 India Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 92 India Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 South Korea Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 94 South Korea Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 95 South Korea Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 South Korea Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 97 South Korea Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 Australia Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 99 Australia Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 100 Australia Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 101 Australia Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 102 Australia Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 103 Thailand Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 104 Thailand Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 105 Thailand Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 106 Thailand Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 107 Thailand Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 108 Latin America Influenza Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 109 Latin America Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 110 Latin America Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 111 Latin America Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 112 Latin America Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 113 Latin America Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 Brazil Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 115 Brazil Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 116 Brazil Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 Brazil Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 118 Brazil Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 119 Mexico Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 120 Mexico Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 121 Mexico Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 122 Mexico Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 123 Mexico Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 124 Argentina Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 125 Argentina Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 126 Argentina Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 127 Argentina Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 128 Argentina Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 129 Middle East and Africa Influenza Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 130 Middle East and Africa Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 131 Middle East and Africa Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 132 Middle East and Africa Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 133 Middle East and Africa Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 134 Middle East and Africa Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 135 South Africa Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 136 South Africa Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 137 South Africa Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 138 South Africa Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 139 South Africa Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 143 Saudi Arabia Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 144 Saudi Arabia Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 145 UAE Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 146 UAE Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 147 UAE Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 148 UAE Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 149 UAE Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 150 Kuwait Influenza Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 151 Kuwait Influenza Vaccine Market, By Indication, 2018 - 2030 (USD Million)
  • Table 152 Kuwait Influenza Vaccine Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 153 Kuwait Influenza Vaccine Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 154 Kuwait Influenza Vaccine Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Influenza Vaccines Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (Vaccine type and indication)
  • Fig. 11 Segment snapshot (Age group and route of administration)
  • Fig. 12 Segment snapshot (Distribution channel)
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Penetration and growth prospect mapping for vaccine type, 2022
  • Fig. 15 SWOT analysis, by factor (Political & legal, economic, and technological)
  • Fig. 16 Industry analysis - Porter's
  • Fig. 17 Vaccination rate against influenza in geriatric population, 2021
  • Fig. 18 Vaccination rate against Hemophilus influenza type b among children aged below 1 year, 2021
  • Fig. 19 Influenza vaccine market: Vaccine type outlook key takeaways
  • Fig. 20 Influenza vaccine market: Vaccine type movement analysis, ((USD Million))
  • Fig. 21 Inactivated market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Live attenuated market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Influenza vaccine market: Indication outlook and key takeaways
  • Fig. 24 Influenza vaccine market: Indication movement analysis
  • Fig. 25 Quadrivalent market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Trivalent market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Influenza vaccine market: Age group outlook and key takeaways
  • Fig. 28 Influenza vaccine market: Age group movement analysis
  • Fig. 29 Pediatric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Influenza vaccination coverage for 6 months to 17 years age group in the U.S.
  • Fig. 31 Adults market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Influenza coverage in adults (%)
  • Fig. 33 Influenza vaccine market: Route of administration outlook and key takeaways
  • Fig. 34 Influenza vaccine market: Route of administration movement analysis
  • Fig. 35 Injection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Nasal spray market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Influenza vaccine market: Distribution channel outlook and key takeaways
  • Fig. 38 Influenza vaccine market: Distribution channel movement analysis
  • Fig. 39 Seasonal influenza vaccine -Total doses distributed (Million)
  • Fig. 40 Place of flu vaccination among vaccinated children 6 months through 17 years
  • Fig. 41 Hospital & pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Government and institutional supply market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Influenza vaccine market revenue, by region, 2022 & 2030 (USD Million)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 Regional marketplace: Key takeaways
  • Fig. 47 North America influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 General reimbursement pattern in the U.S.
  • Fig. 51 Key country dynamics
  • Fig. 52 Canada influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Vaccine testing and approval process in Canada
  • Fig. 54 Europe influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UK influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Germany influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 France influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Spain influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Italy influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Denmark influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Sweden influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Norway influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Rest of Europe influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Asia Pacific influenza vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Japan influenza vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 China influenza vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 China regulatory details
  • Fig. 78 Key country dynamics
  • Fig. 79 India influenza vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Australia influenza vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Thailand influenza vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 South Korea influenza vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 South Korea reimbursement scenario
  • Fig. 87 Rest of Asia Pacific influenza vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Latin America influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Brazil influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Brazil regulation details
  • Fig. 92 Brazil regulation details
  • Fig. 93 Key country dynamics
  • Fig. 94 Mexico influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Regulatory framework
  • Fig. 96 Key country dynamics
  • Fig. 97 Argentina influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Argentina regulatory framework
  • Fig. 99 Rest of Latin America influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 MEA influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 South Africa influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Saudi Arabia influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 UAE influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Kuwait influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Rest of MEA influenza vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key company categorization
  • Fig. 111 Company market positioning
  • Fig. 112 Company market share analysis, 2022
  • Fig. 113 Strategic Framework